Dallas, TX: ReportsandReports announce Mylan Inc.: PharmaVitae Profile Market Research Report in its Store.
Browse complete Report at: http://www.reportsandreports.com/reports/9244-mylan-inc-pharmavitae-profile.html
This analysis examines the historical and forecast performance for Mylan in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
• Benchmark Mylan’s performance against key rivals in the prescription pharmaceutical sector
• Assess how the acquisition of Merck KGaA’s generics division will impact Mylan’s forecast performance
• Consider Mylan’s strategy to maintain its position as the world’s third largest generics company
• Table Of Contents
• ABOUT DATAMONITOR HEALTHCARE 2
• About the PharmaVitae team 2
• Chapter 1 About this profile 3
• PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
• Chapter 2 Executive summary 5
• Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
Mylan: PharmaVitae forecasts at a glance 8
Strategic insight 9
1) 2002-06: Modest growth amid increasing US competition 10
2) 2007-09: M&A sustains position as third largest generics player 10
3) 2010-14: Profit growth via synergies and geographic expansion 11
SWOT analysis 13
Strengths 13
Weaknesses 14
Opportunities 14
Threats 14
• Table of Contents 16
• Table of figures 18
• Chapter 3 Quarterly news update 19
• Product developments 19
Deals and alliances 20
Product deals 20
M&A activity 21
Company announcements 22
• Chapter 4 Company introduction 24
• Key findings 24
Background 25
Key corporate developments 25
M&A history 25
Early M&A boosts branded Prescription pharmaceuticals capacity 26
Matrix acquisition provides API capabilities 26
Acquisition of Merck Generics 27
Mylan/Merck combination becomes third largest global generics player 27
The acquisition expands Mylan’s geographical presence 27
Acquisition of Merck KGaA’s CEE generics business 28
Mylan- potential for further M&A? 28
Current corporate structure 29
Generics Segment 29
Specialty Segment 29
Matrix Segment 30
• Chapter 5 Company sales 31
• Key findings 31
Prescription pharmaceutical sales and growth rate analysis, 2002-14 32
Product analysis 34
Product analysis, 2002-08 34
Product analysis, 2008-14 38
Therapy area analysis 42
Geographic analysis 45
Launch portfolio analysis 48
Launch analysis, 2008-14 48
Molecule type analysis 50
Externalization analysis 53
• Chapter 6 Company financials 56
• Key findings 56
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 57
Operating costs and profit analysis 58
Operating costs and profit analysis, 2002-08 59
Operating cost ratio and profit margin analysis, 2002-08 60
Operating cost ratio and profit margin analysis, 2008-14 61
Operating costs and profit analysis, 2008-14 63
• Chapter 7 Key products and competitors 64
• Overview 64
Central nervous system 65
EpiPen 65
Overview 65
Sales forecast 66
EpiPen sourced through Dey LP acquisition 66
Revenues affected by seasonal factors 66
Competition from Sciele’s TwinJect 66
Next generation device launched in October 2009 67
Respiratory 68
Perforomist 68
Overview 68
Sales forecast 69
Perforomist offers advantages over DuoNeb 69
Competition expected from Sepracor’s Brovana 69
DuoNeb 70
Overview 70
Sales forecast 71
DuoNeb to face declining sales over 2008-14 71
Oncology 72
gen. Xeloda 72
Mylan is forecast to launch a generic version of Roche’s Xeloda (capecitabine) in 2013. This launch date is based upon the patent expiry of the branded colon and breast cancer drug, however, should Mylan successfully challenge this patent protection, Mylan could launch gen. Xeloda at an earlier date. Mylan believes it is the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Xeloda and expects to qualify for 180 days of sole marketing exclusivity once final FDA approval is obtained. Roche filed a lawsuit on April 8 2009 alleging Mylan’s infringement of US patent no. 5,472,949. 72
Overview 72
Sales forecast 73
gen. Copaxone 74
Overview 74
Sales forecast 75
gen. Copaxone is product of Mylan’s alliance with NATCO Pharma 75
Manufacturing complexity will prove an obstacle 75
Sandoz/Momenta offering expected to be first generic to US market 76
gen. fentanyl 77
Overview 77
Sales forecast 78
Mylan owns the majority of the fentanyl patch market 78
Teva enters the Duragesic market in Q3 2008 78
Recall in 2008 expected to have a lasting impact on generic sales 78
gen. Depakote ER 80
Overview 80
Sales forecast 81
Depakote ER generic launched in 2009 81
Sales to decline post-2009 81
• Chapter 8 Appendix 82
• References 82
Abbreviations 82
Exchange rates 83
About Datamonitor 84
About Datamonitor Healthcare 84
Datamonitor consulting 84
Disclaimer 86
ABBREVIATIONS
Browse all : Healthcare Market Research Reports
http://www.reportsandreports.com/cat/healthcare-market-research.html
Browse all : Datamonitor Market Research Reports
http://www.reportsandreports.com/Publisher/datamonitor-market-research.html-market-research.html
Browse all Newly Published Market Research Reports
http://www.reportsandreports.com/LatestReport.aspx
Original Source : PharmaV itae Market
http://www.reportsandreports.com/reports/9244-mylan-inc-pharmavitae-profile.html
Buy Now : Market Research Report
http://www.reportsandreports.com/
Related Reports:
Browse all : Mylan, Inc.-Detailed Product Pipeline
at : http://www.reportsandreports.com/reports/3925-mylan-inc-detailed-product-pipeline.html
Browse all : Mylan, Inc.-Deals & Alliances Report
at : http://www.reportsandreports.com/reports/4376-mylan-inc-deals-alliances-report.html
Browse all : Mylan, Inc.-Therapeutic Competitors
at : http://www.reportsandreports.com/reports/3491-mylan-inc-therapeutic-competitors.html
Browse all : Mylan Inc. – SWOT Analysis
at : http://www.reportsandreports.com/reports/1970-mylan-inc-swot-analysis.html
Browse all : Forest Laboratories Inc.: PharmaVitae Profile
at: http://www.reportsandreports.com/reports/16328-forest-laboratories-inc- pharmavitae- profile.html
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
